Adimab, LLC, the technology leader in the discovery of fully human antibodies and bispecifics, today announced a new collaboration with Kite Pharma, Inc. (Nasdaq:KITE). Under the terms of the agreement, Adimab will use its proprietary platform to generate IgGs against multiple targets selected by Kite. Read More